MILLIPLEX^® Human Soluble Cytokine Receptor Panel

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze 14 analytes in human serum, plasma, and cell culture supernatants.Analytes included: sCD30, sEGFR, sGP130, sIL-1RI, sIL-1RII, sIL-2Rα, sIL-4R, sIL-6R, sRAGE, sTNFRI, sTNFRII, sVEGFR1, sVEGFR2, sVEGFR3Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

Comprehensive Biomarker Coverage: Includes key cytokines, chemokines, and immune modulators relevant to inflammation and immune response pathways.Supports Mechanistic Insights: Facilitates understanding of disease mechanisms such as autoimmune disorders, infections, and chronic inflammation.Lot-to-Lot Consistency: Ensures reproducible results across experiments, improving data reliability.Optimized Panel Design: Pre-selected analytes based on verified inflammatory and immunological targets.

Cytokine receptors constitute an integral part of cytokine biology. Like cytokines, cytokine receptors are involved in normal physiological and pathological processes of almost all disease states. Soluble cytokine receptors naturally arise from genes encoding membrane- bound receptors or are direct derivatives of the receptors themselves. The discovery that soluble cytokine receptors are involved in regulating excessive inflammatory responses and modulating immune events has stimulated significant research interest in their potential role as immunotherapeutic agents. Many of these soluble cytokine receptors can inhibit the binding and biological activity of their cytokine ligands, making them very specific cytokine antagonists.